hydromorphone ER
Selected indexed studies
- Oral hydromorphone extended-release. (Consult Pharm, 2010) [PMID:21172762]
- Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. (Curr Med Res Opin, 2010) [PMID:20429852]
- Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. (Pain Pract, 2013) [PMID:22510252]
_Worker-drafted node — pending editorial review._
Connections
hydromorphone ER is a side effect of
Sources
- Oral hydromorphone extended-release. (2010) pubmed
- Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. (2010) pubmed
- Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. (2013) pubmed
- Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing. (2013) pubmed
- Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. (2012) pubmed
- Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies. (2012) pubmed
- OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs. (2010) pubmed
- Paliperidone-ER: first atypical antipsychotic with oral extended release formulation. (2008) pubmed
- Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis. (2013) pubmed
- Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. (2010) pubmed